

## **REMARKS**

### **Claim Objections:**

The Office Action states that the claims were misnumbered 41-46, but that the Claims have been renumbered 26-30. Applicants thank the examiner for renumbering the claims. However, applicants submit that the claims should have been renumbered Claims 26-31. Applicants are also amending the claims herewith to add new Claims 32-40. Applicants submit that support for the new claims can be found generally throughout the specification.

### **Restriction Requirement:**


The Office Action incorrectly states that Claims 26-30 are pending in the present application. Applicants submit that Claims 26-31 are pending in the present application. Claims 26-31 are the subject of an election/restriction requirement. In response to this requirement, applicants hereby elect the invention of Group II, which comprises Claims 29-31 drawn to a method of inhibiting neovascularization. Since new Claims 32-40 all depend from independent Claim 29, applicants submit that Claims 26-40 should be examiner together.

The Office Action also states that applicants must elect a single species for examination. In response to this requirement, applicants hereby elect the compound 2-methoxyestradiol.

Applicants respectfully request reconsideration of the present application in view of the foregoing remarks. Such action is courteously solicited. Applicants further

request that the Examiner call the undersigned counsel if allowance of the claims can be facilitated by examiner's amendment, telephone interview or otherwise.

Respectfully submitted,

A large, stylized handwritten signature in black ink, appearing to read 'Robert E. Richards', is written over the 'Respectfully submitted,' text.

Robert E. Richards  
Reg. No. 29,105

KILPATRICK STOCKTON LLP  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309-4530  
Tel: (404) 815-6500  
Fax: (404) 815-6555  
Our Docket: 05213-3000 (44040-269288)